Pulmonary Hypertension in General Cardiology Practice

dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorCALDERARO, Daniela
dc.contributor.authorALVES JUNIOR, Jose Leonidas
dc.contributor.authorFERNANDES, Caio Julio Cesar dos Santos
dc.contributor.authorSOUZA, Rogerio
dc.date.accessioned2019-11-06T18:46:20Z
dc.date.available2019-11-06T18:46:20Z
dc.date.issued2019
dc.description.abstractThe finding of pulmonary hypertension (PH) by echocardiography is common and of concern. However, echocardiography is just a suggestive and non-diagnostic assessment of PH. When direct involvement of pulmonary circulation is suspected, invasive hemodynamic monitoring is recommended to establish the diagnosis. This assessent provides, in addition to the diagnostic confirmation, the correct identification of the vascular territory predominantly involved (arterial pulmonary or postcapillary). Treatment with specific medication for PH (phosphodiesterase type 5 inhibitors, endothelin receptor antagonists and prostacyclin analogues) has been proven effective in patients with pulmonary arterial hypertension, but its use in patients with PH due to left heart disease can even be damaging. In this review, we discuss the diagnosis criteria, how etiological investigation should be carried out, the clinical classification and, finally, the therapeutic recommendations for PH.eng
dc.description.abstractO achado de hipertensão pulmonar (HP) em avaliação ecocardiográfica é frequente e preocupante. No entanto, o ecocardiograma é apenas um exame sugestivo e não diagnóstico de HP. Quando se suspeita de acometimento direto da circulação pulmonar, está indicada medida hemodinâmica invasiva para estabelecer o diagnóstico. Essa avaliação permite, além da confirmação diagnóstica, a correta identificação do território vascular predominantemente acometido (arterial pulmonar ou pós-capilar). O tratamento com as medicações específicas de HP (inibidores da fosfodiestarese 5, antagonistas do receptor de endotelina, análogos da prostaciclina e estimulador da guanilil ciclase solúvel) é comprovadamente eficaz para pacientes com hipertensão arterial pulmonar, mas seu uso em pacientes com HP decorrente de doença cardíaca de câmaras esquerdas pode até mesmo ser prejudicial. Discutiremos nesta revisão o critério diagnóstico, a maneira de proceder a investigação etiológica, a classificação clínica e, finalmente, as recomendações terapêuticas na HP.
dc.description.indexMEDLINEeng
dc.identifier.citationARQUIVOS BRASILEIROS DE CARDIOLOGIA, v.113, n.3, p.419-428, 2019
dc.identifier.doi10.5935/abc.20190188
dc.identifier.issn0066-782X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/33977
dc.language.isoeng
dc.language.isopor
dc.publisherARQUIVOS BRASILEIROS CARDIOLOGIAeng
dc.relation.ispartofArquivos Brasileiros de Cardiologia
dc.rightsopenAccesseng
dc.rights.holderCopyright ARQUIVOS BRASILEIROS CARDIOLOGIAeng
dc.subjectHypertensioneng
dc.subjectPulmonaryeng
dc.subjectPulmonary Heart Diseaseeng
dc.subjectEchocardiography/methodseng
dc.subjectPulmonary Diseaseeng
dc.subjectChronic Obstructiveeng
dc.subjectPulmonary Emphysemaeng
dc.subjectPulmonary Fibrosiseng
dc.subjectHipertensão Pulmonar
dc.subjectDoença Cardiopulmonar
dc.subjectEcocardiografia/métodos
dc.subjectDoença Pulmonar Obstrutiva Crônica
dc.subjectEnfisema Pulmonar
dc.subjectFibrose Pulmonar
dc.subject.otherchronic heart-failureeng
dc.subject.otherendothelin receptor antagonismeng
dc.subject.otherdouble-blindeng
dc.subject.otherarterial-hypertensioneng
dc.subject.otherexercise capacityeng
dc.subject.otherclinical statuseng
dc.subject.othersildenafileng
dc.subject.othertrialeng
dc.subject.otherepoprostenoleng
dc.subject.otherdysfunctioneng
dc.subject.wosCardiac & Cardiovascular Systemseng
dc.titlePulmonary Hypertension in General Cardiology Practiceeng
dc.title.alternativeHipertensão Pulmonar na Prática do Cardiologista
dc.typearticleeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.citation.scopus3
hcfmusp.contributor.author-fmusphcDANIELA CALDERARO
hcfmusp.contributor.author-fmusphcJOSE LEONIDAS ALVES JUNIOR
hcfmusp.contributor.author-fmusphcCAIO JULIO CESAR DOS SANTOS FERNANDES
hcfmusp.contributor.author-fmusphcROGERIO DE SOUZA
hcfmusp.description.beginpage419
hcfmusp.description.endpage428
hcfmusp.description.issue3
hcfmusp.description.volume113
hcfmusp.origemWOS
hcfmusp.origem.pubmed31621783
hcfmusp.origem.scieloSCIELO:S0066-782X2019000900419
hcfmusp.origem.scopus2-s2.0-85073464195
hcfmusp.origem.wosWOS:000489577700020
hcfmusp.publisher.cityRIO DE JANEIROeng
hcfmusp.publisher.countryBRAZILeng
hcfmusp.relation.referenceAhearn GS, 2002, CHEST, V122, P524, DOI 10.1378/chest.122.2.524eng
hcfmusp.relation.referenceAlves JL, 2017, SEMIN RESP CRIT CARE, V38, P561, DOI 10.1055/s-0037-1606577eng
hcfmusp.relation.referenceAlves JL, 2015, CHEST, V147, P495, DOI 10.1378/chest.14-1036eng
hcfmusp.relation.referenceAnand I, 2004, LANCET, V364, P347, DOI 10.1016/S0140-6736(04)16723-8eng
hcfmusp.relation.referenceBarst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504eng
hcfmusp.relation.referenceBermejo J, 2018, EUR HEART J, V39, P1255, DOI 10.1093/eurheartj/ehx700eng
hcfmusp.relation.referenceBocchi EA, 2002, CIRCULATION, V106, P1097, DOI 10.1161/01.CIR.0000027149.83473.B6eng
hcfmusp.relation.referenceBoucly A., 2017, EUR RESP J, V50eng
hcfmusp.relation.referenceBursi F, 2012, J AM COLL CARDIOL, V59, P222, DOI 10.1016/j.jacc.2011.06.076eng
hcfmusp.relation.referenceCaliff RM, 1997, AM HEART J, V134, P44, DOI 10.1016/S0002-8703(97)70105-4eng
hcfmusp.relation.referenceDos CJC, 2011, EXPERT REV RESP MED, V5, P675, DOI [10.1586/ers.11.58, 10.1586/ERS.11.58]eng
hcfmusp.relation.referenceFernandes CJC, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00307-2018eng
hcfmusp.relation.referenceCooper TJ, 2013, EUR J HEART FAIL, V15, P119, DOI 10.1093/eurjhf/hfs152eng
hcfmusp.relation.referenceCarvalho Adriana Castro de, 2006, Arq. Bras. Cardiol., V87, pe195, DOI 10.1590/S0066-782X2006001800027eng
hcfmusp.relation.referenceDelcroix M, 2016, CIRCULATION, V133, P859, DOI 10.1161/CIRCULATIONAHA.115.016522eng
hcfmusp.relation.referenceFernandes CJC, 2005, J INHERIT METAB DIS, V28, P603, DOI 10.1007/s10545-005-0603-yeng
hcfmusp.relation.referenceFukui S, 2014, EUR RESPIR J, V43, P1394, DOI 10.1183/09031936.00012914eng
hcfmusp.relation.referenceGalie N, 2016, EUR HEART J, V37, P67, DOI 10.1093/eurheartj/ehv317eng
hcfmusp.relation.referenceGavilanes F, 2017, EUR RESPIR J, V50, DOI 10.1183/1393003.congress-2017.PA2409eng
hcfmusp.relation.referenceGavilanes F, 2016, CURR OPIN PULM MED, V22, P408, DOI 10.1097/MCP.0000000000000300eng
hcfmusp.relation.referenceGavilanes F, 2014, J BRAS PNEUMOL, V40, P609, DOI 10.1590/S1806-37132014000600004eng
hcfmusp.relation.referenceGhio S, 2012, EUR J HEART FAIL, V14, P946, DOI 10.1093/eurjhf/hfs071eng
hcfmusp.relation.referenceGhofrani HA, 2017, LANCET RESP MED, V5, P785, DOI 10.1016/S2213-2600(17)30305-3eng
hcfmusp.relation.referenceHoeper MM, 2006, J AM COLL CARDIOL, V48, P2546, DOI 10.1016/j.jacc.2006.07.061eng
hcfmusp.relation.referenceHoeper MM, 2016, LANCET RESP MED, V4, P306, DOI 10.1016/S2213-2600(15)00543-3eng
hcfmusp.relation.referenceHoette S, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0115-yeng
hcfmusp.relation.referenceHoette S, 2010, J BRAS PNEUMOL, V36, P795, DOI 10.1590/S1806-37132010000600018eng
hcfmusp.relation.referenceHsu S, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02589-2017eng
hcfmusp.relation.referenceHurdman J, 2013, EUR RESPIR J, V41, P1292, DOI 10.1183/09031936.00079512eng
hcfmusp.relation.referenceJabbour A, 2007, EUR J HEART FAIL, V9, P674, DOI 10.1016/j.ejheart.2007.01.008eng
hcfmusp.relation.referenceJardim C, 2014, CURR OPIN PULM MED, V20, P409, DOI 10.1097/MCP.0000000000000086eng
hcfmusp.relation.referenceKalra PR, 2002, INT J CARDIOL, V85, P195, DOI 10.1016/S0167-5273(02)00182-1eng
hcfmusp.relation.referenceKim NH, 2013, J AM COLL CARDIOL, V62, pD92, DOI 10.1016/j.jacc.2013.10.024eng
hcfmusp.relation.referenceKovacs G, 2018, AM J RESP CRIT CAREeng
hcfmusp.relation.referenceLeary PJ, 2018, ANN AM THORAC SOC, V15, P664, DOI 10.1513/AnnalsATS.201803-197EDeng
hcfmusp.relation.referenceLewis GD, 2007, CIRCULATION, V116, P1555, DOI 10.1161/CIRCULATIONAHA.107.716373eng
hcfmusp.relation.referenceLuscher TF, 2002, CIRCULATION, V106, P2666, DOI 10.1161/01.CIR.0000038497.80095.E1eng
hcfmusp.relation.referenceMaron BA, 2016, CIRCULATION, V133, P1240, DOI 10.1161/CIRCULATIONAHA.115.020207eng
hcfmusp.relation.referenceMasy M, 2018, EUR RADIOL, V28, P5100, DOI 10.1007/s00330-018-5467-2eng
hcfmusp.relation.referenceMcGoon MD, 2013, J AM COLL CARDIOL, V62, pD51, DOI 10.1016/j.jacc.2013.10.023eng
hcfmusp.relation.referenceMcLaughlin VV, 2013, J AM COLL CARDIOL, V62, pD73, DOI 10.1016/j.jacc.2013.10.034eng
hcfmusp.relation.referenceMoreira EM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130072eng
hcfmusp.relation.referenceNaeije R, 2013, EUR RESPIR J, V41, P217, DOI 10.1183/09031936.00074312eng
hcfmusp.relation.referencePacker M, 2005, J CARD FAIL, V11, P12, DOI 10.1016/j.cardfail.2004.05.006eng
hcfmusp.relation.referencePacker M, 2017, JACC-HEART FAIL, V5, P317, DOI 10.1016/j.jchf.2017.02.021eng
hcfmusp.relation.referencePalazzini M, 2018, EUR J HEART FAIL, V20, P248, DOI 10.1002/ejhf.860eng
hcfmusp.relation.referenceRedfield MM, 2013, JAMA-J AM MED ASSOC, V309, P1268, DOI 10.1001/jama.2013.2024eng
hcfmusp.relation.referenceRICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203eng
hcfmusp.relation.referenceRudski LG, 2010, J AM SOC ECHOCARDIOG, V23, P685, DOI 10.1016/j.echo.2010.05.010eng
hcfmusp.relation.referenceSeeger W, 2013, J AM COLL CARDIOL, V62, pD109, DOI 10.1016/j.jacc.2013.10.036eng
hcfmusp.relation.referenceSimonneau G, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01913-2018eng
hcfmusp.relation.referenceSimonneau G, 2009, J AM COLL CARDIOL, V54, pS43, DOI 10.1016/j.jacc.2009.04.012eng
hcfmusp.relation.referenceSouza R, 2009, SEMIN RESP CRIT CARE, V30, P448, DOI 10.1055/s-0029-1233314eng
hcfmusp.relation.referenceStasch JP, 2013, HANDB EXP PHARMACOL, V218, P279, DOI 10.1007/978-3-642-38664-0_12eng
hcfmusp.relation.referenceSUETA CA, 1995, AM J CARDIOL, V75, pA34, DOI 10.1016/S0002-9149(99)80381-6eng
hcfmusp.relation.referenceSutsch G, 1998, CIRCULATION, V98, P2262, DOI 10.1161/01.CIR.98.21.2262eng
hcfmusp.relation.referenceTunariu N, 2007, J NUCL MED, V48, P680, DOI 10.2967/jnumed.106.039438eng
hcfmusp.relation.referenceVachiery JL, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01897-2018eng
hcfmusp.relation.referenceVachiery JL, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01886-2017eng
hcfmusp.relation.referenceVachiery JL, 2013, J AM COLL CARDIOL, V62, pD100, DOI 10.1016/j.jacc.2013.10.033eng
hcfmusp.scopus.lastupdate2024-06-09
relation.isAuthorOfPublicationd9e02a87-4fb1-48da-9f5b-68396a8d2b36
relation.isAuthorOfPublication396f9dc0-9e3c-4056-a2c4-1ad9f2faaf5d
relation.isAuthorOfPublication8d16de87-4cf2-475c-b186-0eb934027217
relation.isAuthorOfPublication502d5aeb-c5a4-4275-8c07-02d25223d6d1
relation.isAuthorOfPublication.latestForDiscoveryd9e02a87-4fb1-48da-9f5b-68396a8d2b36
Arquivos
Pacote Original
Agora exibindo 1 - 2 de 2
Carregando...
Imagem de Miniatura
Nome:
art_CALDERARO_Pulmonary_Hypertension_in_General_Cardiology_Practice_2019_eng.PDF
Tamanho:
437.32 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Carregando...
Imagem de Miniatura
Nome:
art_CALDERARO_Pulmonary_Hypertension_in_General_Cardiology_Practice_2019_por.PDF
Tamanho:
450.38 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (Portuguese)